{"schema_version":"1","generated_at":"2026-11-11T08:04:58.279Z","data_as_of":null,"url":"https://www.findmykol.com/kol/uchenna-njiaju","json_url":"https://www.findmykol.com/kol/uchenna-njiaju/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"uchenna-njiaju","name":"Uchenna Njiaju","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Colorado Springs","state":"CO","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1063556736","openalex":"A5082901504"},"summary":"Uchenna Njiaju is an Oncology physician. OpenAlex indexes 15 publications with 250 citations (h-index 9).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":15,"cited_by_count":250,"h_index":9,"latest_activity_year":2023,"source":"works"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":10,"shown":3,"withheld":7,"rows":[{"payer":"Eli Lilly","program_year":2025,"amount_usd":88129.05,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063556736"},{"payer":"Eli Lilly","program_year":2024,"amount_usd":103557.93,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063556736"},{"payer":"Eli Lilly","program_year":2023,"amount_usd":2141.33,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063556736"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1063556736","source":"payments"},"prescribing":{"data_year":2024,"areas_total":11,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":49.5,"classes_total":6,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":34.6,"drugs":[{"name":"Letrozole","share_pct":59.6},{"name":"Anastrozole","share_pct":32},{"name":"Exemestane","share_pct":8.4}],"max_beneficiaries":84},{"class":"Estrogen Agonist/Antagonist","setting":"prescribed","share_pct":5,"drugs":[{"name":"Tamoxifen Citrate","share_pct":100}],"max_beneficiaries":20}]},{"area":"Metabolism & gastrointestinal","share_pct":12.5,"classes_total":5,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":5,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":31},{"class":"Potassium supplement","setting":"prescribed","share_pct":4.3,"drugs":[{"name":"Potassium Chloride","share_pct":100}],"max_beneficiaries":19}]},{"area":"Nervous system","share_pct":11.9,"classes_total":5,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":4.4,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":19},{"class":"Phenothiazine","setting":"prescribed","share_pct":4.4,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":31}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":2.8,"facility_pct":97.2},"source":"medicare"},"publications":{"total":15,"shown":5,"withheld":10,"matched_by":"OpenAlex author record","recent":[{"title":"A 40-Year-Old Woman With a New Triple-Negative Breast Mass, Shown on Biopsy to Be Metaplastic Carcinoma.","year":2016,"journal":"PubMed","status":"verified"},{"title":"Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion","year":2015,"journal":"BMC Cancer","source_url":"https://doi.org/10.1186/s12885-015-1075-6","status":"verified"},{"title":"Neo‐adjuvant Capecitabine Chemotherapy in Women with Newly Diagnosed Locally Advanced Breast Cancer in a Resource‐poor Setting (Nigeria): Efficacy and Safety in a Phase II Feasibility Study","year":2013,"journal":"The Breast Journal","source_url":"https://doi.org/10.1111/tbj.12149","status":"verified"},{"title":"Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study","year":2013,"journal":"Clinical Breast Cancer","source_url":"https://doi.org/10.1016/j.clbc.2013.10.018","status":"verified"},{"title":"Abstract P3-12-10: Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin oncology network study","year":2013,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/0008-5472.sabcs13-p3-12-10","status":"verified"}],"source":"works"},"contact":{"address_1":"525 N FOOTE AVE","address_2":"STE 202","city":"Colorado Springs","state":"CO","zip":"809094501","phone":"719-365-6568","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1063556736","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":7,"publications":10}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2013-07-12","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}